| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1060028013513009 |
| P698 | PubMed publication ID | 24259661 |
| P2093 | author name string | Kevin B Kim | |
| Van Anh Trinh | |||
| Jennifer E Davis | |||
| Jaime E Anderson | |||
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance | Q28282963 | ||
| Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions | Q30486572 | ||
| Melanoma brain metastases and vemurafenib: need for further investigation | Q36512866 | ||
| Analysis of dermatologic events in vemurafenib-treated patients with melanoma | Q36714398 | ||
| Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features | Q37036930 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| Novel mitogen-activated protein kinase kinase inhibitors | Q37828536 | ||
| Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management | Q38005994 | ||
| Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma | Q38026916 | ||
| Resistance to BRAF-targeted therapy in melanoma | Q38071800 | ||
| Which drug, and when, for patients with BRAF-mutant melanoma? | Q38078136 | ||
| Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials | Q38502534 | ||
| Determinants of outcome in melanoma patients with cerebral metastases | Q38517839 | ||
| Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. | Q39610715 | ||
| Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. | Q40298916 | ||
| Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. | Q41675125 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| Melanoma | Q56428909 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 519-529 | |
| P577 | publication date | 2013-11-20 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Dabrafenib therapy for advanced melanoma | |
| P478 | volume | 48 |
| Q38439387 | Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition |
| Q38281838 | BRAF inhibitors: experience in thyroid cancer and general review of toxicity |
| Q64986104 | Dabrafenib and its use in the treatment of metastatic melanoma. |
| Q50954724 | Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation |
| Q38370667 | Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature |
| Q35578108 | Imaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administrationa |
| Q26738377 | Metastatic disease from uveal melanoma: treatment options and future prospects |
| Q23923997 | Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting |
Search more.